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p53 tumor suppressor gene is the most commonly mutated gene in human and mouse cancers. Disruption of the p53 and Rb
pathways is a fundamental trend of most human cancer cells. Inactivation of CDKN2A can lead to deregulation of these two
pathways. Genetic abnormalities in CDKN2A gene have been well documented in human melanoma but their involvement in
human nonmelanoma skin cancer (NMSC) and in particular in squamous cell carcinoma (SCC) is less clear. Several studies have
shown that human SCCs harbour unique mutations in the p53 gene as well as inactivation of the CDKN2A gene. While mutations
in the p53 gene are induced by UV radiation and represent tumor initiating events, the majority of alterations detected in the
CDKN2A gene do not appear to be UV-dependent. In conclusion, in addition to p53 mutations, silencing of the CDKN2A gene
might play a signiﬁcant role in SCC development.
Copyright © 2007 A. Paciﬁco and G. Leone. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Cutaneous SCC is the second most common malignancy di-
agnosed in Caucasian population. Its incidence varies con-
siderablyandisreportedtobeincreasingworldwide[1].SCC
arise on sun-exposed areas of the skin and may behave ag-
gressively, resulting in recurrence or metastasis [2].
Many genetic and environmental factors are known to
contribute to the development of SCCs, the most important
being repeated exposures to the ultraviolet (UV) in the sun-
light [3, 4]. Epidemiological studies clearly showed a corre-
lation between repeated exposure to UV radiation in child-
hood and an increased incidence of skin cancer especially in
Caucasians with fair skin [5].
Wavelengths in the region (290–320nm) of the solar
spectrum are absorbed into the skin producing erythema,
burns, and eventually skin cancer. Laboratory studies have
shown that UVB region of the solar spectrum is responsible
for these eﬀects [6]. Chronic UV exposure may cause mu-
tations in cellular DNA unless photoproducts are repaired,
and the accumulation of genetic abnormalities leads to tu-
mor formation [7].
It is widely accepted that SCCs develop through a multi-
step process that involves the activation of protooncogenes
and/or inactivation of tumor suppressor genes. The initial
damage takes place in the DNA after which DNA repair is
undertaken by a complex array of gene repair proteins [8].
Several studies have shown that SCCs harbour unique
mutations in the p53 tumor suppressor gene that are not
commonly found in other human cancers. These mutations
termed UV signature mutations, consist of single (C → T)
and double (CC → TT) pyrimidine base substitutions and
have been identiﬁed either in premalignant or in malignant
cutaneous squamous lesions [9]. In fact, the ﬁnding that p53
mutations are present in actinic keratosis (AK) and in sun-
damaged skin suggests that p53 mutations arise early dur-
ing the development of SCC [10]. This hypothesis is sup-
ported by laboratory studies demonstrating that clones of
keratinocytes with mutant p53 protein and p53 mutations
can be detected in UV-irradiated mouse skin well before the
appearance of skin tumors [11, 12]. The presence of UV sig-
nature mutations at dipyrimidine sites of the p53 gene indi-
catesstronglytheroleofUVradiationinskincarcinogenesis.
Disruptionofthep53andRbtumorsuppr essorpath wa ys
is a fundamental trend of most human cancer cells. In tu-
morigenesis, loss of Rb function can occur by direct inacti-
vation of the Rb gene itself through mutation or by dereg-
ulation of the genes controlling Rb phosphorylation sta-
tus. These last alterations include cyclin-D1 gene ampliﬁca-
tion,CDK4activatingmutations,andalsogeneampliﬁcation2 Journal of Biomedicine and Biotechnology
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Figure 1: Molecular events following UV exposure.
and inactivation of the inhibitors of CDK4, the INK4 family
[13, 14].
The CDKN2A (INK4a/ARF) locus at 9p21 encodes two
alternatively spliced proteins, p16INK4a andp14ARF, function-
ing as cell cycle inhibitors [14]. Several studies have shown
that a subset of SCCs of the skin carries mutations in the
CDKN2Atumorsuppressorgene[15].Althoughfrequentin-
activation of CDKN2A h a sb e e nr e p o r t e di nS C C sf r o mx e -
roderma pigmentosum patients [16], its involvement in spo-
radic SCCs is not completely understood yet. The studies
conducted by Souﬁr et al. and Brown et al. showed inactiva-
tion of CDKN2A in the 24% and 76% of SCCs, respectively,
(see [3, 17]).
2. p53 INACTIVATION
The p53 tumor suppressor gene encodes for p53-kd nuclear
phosphoprotein, which has been named “guardian of the
genome.” It functions as a regulator of cellular responses to
genotoxic injury, including exposure to ultraviolet radiation.
It arrests cell division at G1 phase to allow DNA repair. In
particular, it has been demonstrated that in this pathway
p21WAF1/CIP1 acts as an inhibitor of the cyclin-dependent ki-
nase (CDK) whose induction is associated with the expres-
sion of p53 [18]. p21 mediates cell cycle arrest by binding
to and inactivating the cyclin D/CDK4, cyclin D/CDK6, and
cyclin E/CDK2 complexes. When D-type cyclins are com-
plexed with CDK4/6 phosphorylate serine and threonine
residues on the retinoblastoma (Rb) protein, this tethers the
Rb from E2F transcriptional factors, thereby enabling the
E2F-mediated activation of a series of target genes essential
for S phase entry. The overexpression of p21, however, causes
the accumulation of hypophosphorylated Rb (pRb) and the
sequestration of E2F, which causes the cell to be arrested in
G21phase[19].Ifthegenomicinsultisextensiveinstead,p53
induces apoptosis in an eﬀort to eliminate potentially trans-
formed cells (Figure 1). Inactivation of the p53 gene, either
by mutation or other mechanisms, results in an increased
rateofaccumulationofgeneticdamageincellsandpromotes
tumor formation [20].
In normal conditions, a very small amount of p53 pro-
tein is present in cells; in response to DNA damage, protein
accumulates, cell division is inhibited, and DNA repair oc-
curs. It is thought that inhibition of cell division enables the
cell to repair damaged DNA before undergoing replication
[21]. The p53 gene is a common target for genetic alteration
in human and mouse cancers and often speciﬁc carcinogens
i n d u c es p e c i ﬁ cm u t a t i o n si nt h i sg e n e[ 22].
FollowingchronicUVexposure,mistakesassociatedwith
DNA repair and replication can result into mutations in the
p53 gene, especially C → T and CC → TT transitions at
dipyrimidine sites, considered as UV molecular signature.
The p53 mutation in keratinocytes is probably an initiating
event in UV skin carcinogenesis [23].
As UV signature mutations in the p53 gene are already
presentinbenignprecursorlesionsofsquamouscellcarcino-
mas (AK), they appear to be an early step in the UV carcino-
genesis. In the experiments with hairless mice, microscopic
clusters of epidermal cells overexpressing mutant p53 occur
long before skin carcinomas become visible [11]. Such clus-
ters are also found in sun-exposed human skin [10]. Most of
human non melanoma skin cancer are found to bear muta-
tions in the p53 g e n e .B r a s he ta l .[ 24] showed p53 mutations
in 58% of human SCCs analyzed (3/24 showed CC → TT
transition and 5/24 had C → T base change) [22]. In a re-
cent study, Bolshakov et al. analyzed 342 human NMSC and
found p53 mutations in 28/80 aggressive SCCs and in 28/56
non aggressive SCCs. About 71% of the detected p53 muta-
tions were UV signature mutations [25].
Experiments to determine the timing of p53 mutation in
relation to skin cancer development have been performed
in the mouse model of photocarcinogenesis because thisA. Paciﬁco and G. Leone 3
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CDK4 binding to cyclin D preventing inactivation of pRb. Hypophosphorylated pRb represses E2F-dependent genes blocking G1/S cell cycle
progression. p14ARF/p53 pathway: p53 is targeted by MDM2 for ubiquitination and degradation. In response to oncogenic signals, p14ARF
induces MDM2 molecular relocalization, thereby preventing MDM2-p53 interactions and resulting in the stabilization of p53.
model is easily referable to UV irradiation and sample col-
lection at various time points during the carcinogenesis pro-
tocol. Ananthaswamy et al. have shown that p53 mutations
in mouse skin arise very early during UV carcinogenesis by
using a very sensitive mutation-speciﬁc PCR technique for
the early detection of p53 mutations in UVB-irradiated C3H
mice. They were able to detect p53 mutations at 4th week of
UVirradiation andthefrequencyof p53mutationsincreased
progressively and reached 50% at 12th week of chronic UV
exposure. The real p53 mutations frequency observed in this
study is probably higher than the one described because only
tandem CC → TT mutations were analyzed [12]. In addi-
tion to C3H mice, Ouhtit et al. used SKH-hr1 mice to de-
termine the timing of p53 mutations during UV carcino-
genesis. Interestingly, p53 mutations were detected as early
as 1st week of chronic UV irradiation and the mutation fre-
quency reached 80%–90% by 4–8 weeks [26]. Both the early
appearance and the high frequency of p53 mutations in UV-
irradiated SKH-hr1 mice skin can be explained with the fact
that either C → To rC C→ TT mutations were analyzed in
this study.
In a recent study, Melnikova et al. investigated whether
discontinuation of UV exposure before the onset of skin tu-
mors results in the disappearance of p53 mutations in the
skin of SKH-hr1 mice. Their results indicated that despite
discontinuationafter8weeks,UVirradiationresultsin100%
skin tumor incidence, although the kinetics of tumor occur-
rence is greatly delayed. In terms of human relevance these
results suggest that early life exposure to UV may intro-
duce p53 gene mutations in epidermal keratinocytes as well
as keratinocytes progenitors. While some p53-mutated ker-
atinocytes may be eliminated via diﬀerentiation and epider-
mal desquamation, others, may still persist and eventually
give rise to skin tumors even in the absence of further UV
exposure. Thus, cancer development can be delayed but not
deﬁnitively abrogated upon further avoidance of exposure to
UV radiation [27].
3. CDKN2A INACTIVATION
The presence of p53 mutations in sun-exposed skin and pre-
malignant lesions suggest that p53 mutations arise early and
may be required but not suﬃcient for tumor development.
Therefore, it is expected that additional genetic alterations in
oncogenes and tumor suppressor genes are essential for the
development of SCCs.
The CDKN2A locus at 9p21 (Figure 2) is frequently in-
activated in human cancers and it consists of two overlap-
ping genes that encode two unrelated proteins, p16INK4a and
p14ARF, functioning as cell cycle inhibitors.
p16INK4a and p14ARF share the same exon 2 but having a
distinct exon 1, exon 1α and exon 1β,r e s p e c t i v e l y .B e c a u s e
exon 1β splices into common exons 2 and 3 in a diﬀerent
reading frame, the resulting p14ARF bears no similarity to
p16INK4a. It is well established that p14ARF plays a role in
cell cycle control linking the p16INK4a/Rb pathway and the
p53/Rb pathway. Upon phosphorylation of Rb,E 2 Fi sa c t i -
vated and promotes induction of p14ARF, which in turn se-
questers MDM2 and thereby prevents degradation and nu-
clear export of p53. Both p16INK4a and p14ARF transcripts by
theirinteractionswithpRbandp53areimportantinregulat-
ing the proliferation of normal and tumorigenic squamous
epithelial cells [28, 29].4 Journal of Biomedicine and Biotechnology
Inactivation of the tumor suppressor gene CDKN2A can
occur in a variety of genetic mechanisms including muta-
tions and deletions. In addition, hypermethylation of the
CpG islands of gene promoter is an eﬀective means of gene
silencing in a variety of tumors. Inactivation of CDKN2A by
deletion, mutation, or promoter hypermethylation in a wide
range of malignancies has been documented [30].
It has been shown by Souﬁr et al. that SCCs from xer-
oderma pigmentosum patients contain mutations in CDK-
N2A gene in 13/28 SCCs and 54% of mutations detected at
CDKN2A locus were UV signature mutations [4].
In order to determine the involvement of CDKN2A gene
in sporadic SCCs, Saridaki et al. performed the allelic im-
balance analysis and the mutational analysis on 22 SCCs and
on 5 Bowen’s disease specimens. Their results indicated that
52% of specimens exhibited loss of etherozygosity (LOH) in
at least one microsatellite marker whereas only 2/27 sam-
ples exhibited microsatellite instability. Mutational analysis
r e v e a l e dt h ep r e s e n c eo fab a s es u b s t i t u t i o ni ne x o n1 α of 1
tumor and the presence of a C → T transition in exon 2 in a
second tumor [31].
Brown et al. analyzed 30 cutaneous SCCs from 29 pa-
tients immunosuppressed and 10 tumors from immuno-
competent patients and have shown that the total frequency
of 9p21 alterations was 76%, with abnormalities of p16INK4a
detected in 53% of tumor analyzed and of p14ARF in 64%
of the tumors. Promoter methylation was the predominant
mechanism of inactivation for both genes. Biallelic events
were common [17].
Murao et al. examined the epigenetic abnormalities of a
w i d er a n g eo fc a n c e r - r e l a t e dg e n e s( CDH1, p16, p15, RB1,
p14, DAPK1, MGMT, RASSF1, PTEN, PRDM2,a n dp53)i n
20sporadicSCCsfrom20immunocompetentpatients.Their
results showed that although the frequency of methylation of
p16INK4a,Rb1,andp14ARF wasnothigh,methylationofthese
genes in combination with mutation analysis of CDKN2A
and p53 revealed that 70% of cases had abnormalities of the
RB1/p16 and/or p53 pathway through either genetic or epi-
genetic mechanisms, except for epigenetic abnormalities of
p53 itself [32].
All these ﬁndings emphasize the importance of CDKN2A
tumor suppressor gene in the pathogenesis of SCC.
4. CONCLUSIONS
UV radiation present in the sunlight is a potent carcinogen.
Recent advances in cellular and molecular biology have clari-
ﬁed some of the mechanisms of photocarcinogenesis includ-
ing the formation of DNA photoproducts, DNA repair, mu-
tation of protooncogenes, and tumor suppressor genes. It is
well established that UV radiation induces mutations in the
p53 gene and that these mutations arise very early during
photocarcinogenesis.
In addition to mutations in the p53 tumor suppressor
gene, genetic alterations in CDKN2A gene leading to loss of
expression of p16Ink4a and p14ARF proteins may also play an
important role in the development of human NMSC.
Several studies have shown that human SCC harbor
unique mutations in the p53 gene as well as inactivation of
the CDKN2A gene. While mutations in the p53 gene are in-
ducedbyUVradiationandrepresenttumorinitiatingevents,
the majority of the alterations detected in the CDKN2A gene
do not appear to be UV dependent. Probably these genetic
alterations arise spontaneously, probably during tumor pro-
gression.
In conclusion, from results of several recent studies we
can assume that mutations in p53 and CDKN2A genes may
contribute to the initiation and progression of UV-induced
skin tumors.
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